Journal
JOURNAL OF CONTROLLED RELEASE
Volume 331, Issue -, Pages 246-259Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2021.01.020
Keywords
Pancreatic cancer; gene silencing; RNA delivery; tumor stroma
Ask authors/readers for more resources
Despite extensive research and development in anticancer drugs, patient survival for pancreatic cancer has seen limited improvement. Gene silencing shows promise in inhibiting tumor-promoting genes in both tumor cells and stromal cells. Non-viral delivery systems for small RNAs and potential immunological implications are important in gene silencing therapy for pancreatic cancer.
Despite intensive research efforts and development of numerous new anticancer drugs and treatment strategies over the past decades, there has been only very limited improvement in overall patient survival and in effective treatment options for pancreatic cancer. Current chemotherapy improves survival in terms of months and death rates in pancreatic cancer patients are almost equivalent to incidence rates. It is imperative to develop new therapeutic approaches. Among them, gene silencing shows promise of effectiveness in both tumor cells and stromal cells by inhibiting tumor-promoting genes. This review summarizes potential targets for gene silencing in both pancreatic cancer cells and abundant stromal cells focusing on non-viral delivery systems for small RNAs and discusses the potential immunological implications. The review concludes with the importance of multifactorial therapy of pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available